{
    "nct_id": "NCT04829604",
    "official_title": "A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd",
    "inclusion_criteria": "* Age ≥ 18 years and older\n* Life expectancy ≥ 6 months\n* Unresectable or metastatic breast cancer subjects\n* Presence of at least one measurable lesion per RECIST v 1.1\n* Subjects must have HER2 positive breast cancer per ASCO-CAP guidelines, documented in a CLIA lab pathology report\n* Subjects must have had prior treatment with no more than 5 prior regimens of systemic treatment HER-2 targeting therapy or chemotherapy in the metastatic setting. One of these prior treatments must have been treatment with T-DXd.\n* Subjects with stable brain metastases\n* Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade ≤1 as per the NCI-CTCAE v 5.0, except alopecia, vitiligo, Grade 2 peripheral neuropathy, or endocrine toxicities that are stable on hormone replacement.\n* Adequate organ functions\n* Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Any subject who meets any of the following criteria is excluded from the study:\n\n* History of allergic reactions to any component of ARX788.\n* Prior history of interstitial lung disease, pneumonitis, or other clinically significant lung disease. Any requirement for supplemental oxygen.\n* Any active ocular infections or chronic corneal disorders\n* History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, cardiac arrhythmia, or myocardial infarction within 6 months prior to enrollment\n* Grade 3 to 4 peripheral neuropathy (NCI CTCAE v 5.0).\n* History of unstable central nervous system (CNS) metastases\n* Radiotherapy outside of the brain administered < 7 days prior to first dose of ARX788\n* Current severe, uncontrolled systemic disease (eg, clinically significant cardiovascular, pulmonary, or metabolic diseases)\n* Any uncontrollable intercurrent illness, infection (including subjects with active, symptomatic Covid-19 infections), or other conditions that could limit study compliance or interfere with assessments\n* Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 14 days before the first dose of ARX788",
    "miscellaneous_criteria": "Key"
}